These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

291 related articles for article (PubMed ID: 2373859)

  • 1. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular requirements for the full expression of antitumor immunity.
    Campbell MJ; Esserman L; Byars NE; Allison AC; Levy R
    J Immunol; 1990 Aug; 145(3):1029-36. PubMed ID: 2373859
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idiotype vaccination against murine B cell lymphoma. Humoral and cellular responses elicited by tumor-derived immunoglobulin M and its molecular subunits.
    Campbell MJ; Carroll W; Kon S; Thielemans K; Rothbard JB; Levy S; Levy R
    J Immunol; 1987 Oct; 139(8):2825-33. PubMed ID: 3498771
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Idiotype vaccination against murine B cell lymphoma. Inhibition of tumor immunity by free idiotype protein.
    Kaminski MS; Kitamura K; Maloney DG; Levy R
    J Immunol; 1987 Feb; 138(4):1289-96. PubMed ID: 3492546
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Anti-idiotypic mechanisms involved in suppression of a mouse B cell lymphoma, BCL1.
    George AJ; Tutt AL; Stevenson FK
    J Immunol; 1987 Jan; 138(2):628-34. PubMed ID: 3491853
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Idiotype vaccination post-bone marrow transplantation for B-cell lymphoma: initial studies in a murine model.
    Kwak LW; Campbell M; Levy R
    Cancer Detect Prev; 1991; 15(4):323-5. PubMed ID: 1794139
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DNA vaccination against the idiotype of a murine B cell lymphoma: mechanism of tumor protection.
    Syrengelas AD; Levy R
    J Immunol; 1999 Apr; 162(8):4790-5. PubMed ID: 10202021
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Growth inhibition of a B cell leukemia: evidence implicating an anti-idiotype immune response for protective tumor immunity.
    Ciavarra RP; Vitetta ES; Forman J
    J Immunol; 1986 Aug; 137(4):1371-5. PubMed ID: 2426362
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Idiotype variants emerging after anti-idiotype monoclonal antibody therapy of a murine B cell lymphoma.
    Weiner GJ; Kaminski MS
    J Immunol; 1989 Jan; 142(1):343-51. PubMed ID: 2783325
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Idiotype vaccination strategies against a murine B-cell lymphoma: dendritic cells loaded with idiotype and bispecific idiotype x anti-class II antibodies can protect against tumor growth.
    Bohlen H; Thielemanns K; Tesch H; Engert A; Wolf HJ; van Camp B; Urbain J; Diehl V
    Cytokines Mol Ther; 1996 Dec; 2(4):231-8. PubMed ID: 9384709
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Bispecific anti-idiotype/anti-CD3 antibody therapy of murine B cell lymphoma.
    Weiner GJ; Hillstrom JR
    J Immunol; 1991 Dec; 147(11):4035-44. PubMed ID: 1834746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The role of tumor-specific Lyt-1+2- T cells in eradicating tumor cells in vivo. I. Lyt-1+2- T cells do not necessarily require recruitment of host's cytotoxic T cell precursors for implementation of in vivo immunity.
    Fujiwara H; Fukuzawa M; Yoshioka T; Nakajima H; Hamaoka T
    J Immunol; 1984 Sep; 133(3):1671-6. PubMed ID: 6205091
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cellular interactions and the role of interleukin 2 in the expression and induction of immunity against a syngeneic murine sarcoma.
    Chou T; Shu S
    J Immunol; 1987 Sep; 139(6):2103-9. PubMed ID: 2957448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of humoral immune responses and tumor immunity in mice immunized with recombinant SV40 large tumor antigen and a monoclonal anti-idiotype.
    Shearer MH; Bright RK; Kennedy RC
    Cancer Res; 1993 Dec; 53(23):5734-9. PubMed ID: 7694794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Idiotypic vaccination for B-cell malignancies as a model for therapeutic cancer vaccines: from prototype protein to second generation vaccines.
    Ruffini PA; Neelapu SS; Kwak LW; Biragyn A
    Haematologica; 2002 Sep; 87(9):989-1001. PubMed ID: 12217812
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Anti-idiotypic antibodies recognizing stable epitopes limit the emergence of idiotype variants in a murine B cell lymphoma.
    Weiner GJ; Kaminski MS
    J Immunol; 1990 Mar; 144(6):2436-45. PubMed ID: 1690244
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Tumor-specific idiotype vaccines. II. Analysis of the tumor-related network response induced by the tumor and by internal image antigens (Ab2 beta).
    Raychaudhuri S; Saeki Y; Chen JJ; Iribe H; Fuji H; Kohler H
    J Immunol; 1987 Jul; 139(1):271-8. PubMed ID: 2953815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anti-tumor immunity induced by an anti-idiotype antibody mimicking human Her-2/neu.
    Mohanty K; Saha A; Pal S; Mallick P; Chatterjee SK; Foon KA; Bhattacharya-Chatterjee M
    Breast Cancer Res Treat; 2007 Jul; 104(1):1-11. PubMed ID: 17004107
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vaccination with membrane-associated idiotype provides greater and more prolonged protection of animals from tumor challenge than the soluble form of idiotype.
    Ghosh SK; White LM; Ghosh R; Bankert RB
    J Immunol; 1990 Jul; 145(1):365-70. PubMed ID: 1972719
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of a murine B cell lymphoma with monoclonal antibodies and IL 2.
    Berinstein N; Levy R
    J Immunol; 1987 Aug; 139(3):971-6. PubMed ID: 3496394
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The collaboration of both humoral and cellular HER-2/neu-targeted immune responses is required for the complete eradication of HER-2/neu-expressing tumors.
    Reilly RT; Machiels JP; Emens LA; Ercolini AM; Okoye FI; Lei RY; Weintraub D; Jaffee EM
    Cancer Res; 2001 Feb; 61(3):880-3. PubMed ID: 11221874
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.